For the quarter ending 2025-09-30, AMPH had $28,576K increase in cash & cash equivalents over the period. $47,235K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net revenues | 191,840 | - |
| Payroll expense | 45,871 | - |
| Materials and supplies | 7,648 | - |
| Clinical trials expense | 352 | - |
| Depreciation and amortization expense | 14,129 | - |
| Stock-based compensation expense | 6,297 | - |
| Consulting and outside services expense | 9,922 | - |
| Advertising & promotional expense | 3,374 | - |
| Other segment items | 78,696 | - |
| Interest income | 10,266 | - |
| Interest expense | 6,284 | - |
| Income tax provision | 4,163 | - |
| Net income | 17,350 | 56,315 |
| Loss on disposal of assets | -1 | -32 |
| Loss (gain) on interest rate swaps and foreign currency transactions, net | -285 | -1,736 |
| Depreciation of property, plant, and equipment | 7,860 | 15,716 |
| Amortization of intangible assets | 6,269 | 12,509 |
| Operating lease right-of-use asset amortization | 1,639 | 3,221 |
| Amortization of discounts, premiums, and debt issuance costs | 885 | 1,604 |
| Share-based compensation expense | 6,297 | 14,775 |
| Accounts receivable, net | 13,791 | -4,192 |
| Inventories | -5,860 | 35,932 |
| Prepaid expenses and other assets | 7,941 | 5,417 |
| Income tax refunds, deposits, and payable, net | -4,122 | 8,467 |
| Operating lease liabilities | -1,591 | -2,362 |
| Accounts payable and accrued liabilities | 25,338 | 12,747 |
| Net cash provided by operating activities | 52,583 | 70,669 |
| Purchases and construction of property, plant, and equipment | 5,348 | 21,262 |
| Purchase of intangible assets | 0 | 2,250 |
| Purchase of investments | 35,206 | 15,619 |
| Maturity of investments | 22,527 | 51,322 |
| Deposits and other assets | 1,592 | 2,335 |
| Net cash used in investing activities | -19,619 | 9,856 |
| Proceeds from equity plans, net of withholding tax payments | 379 | 494 |
| Purchase of treasury stock | 4,850 | 50,220 |
| Debt issuance costs | 4 | 675 |
| Proceeds from borrowing under lines of credit | 172 | 5,771 |
| Principal payments on long-term debt | 44 | 75 |
| Net cash provided by (used in) financing activities | -4,347 | -44,705 |
| Effect of exchange rate changes on cash | -41 | 260 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 28,576 | 36,080 |
| Cash and cash equivalents at beginning of period | 151,844 | - |
| Cash and cash equivalents at end of period | 216,500 | - |
Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. (AMPH)